logo
Most important takeaway from Rays' 1st half? Chance to make the 2nd fun

Most important takeaway from Rays' 1st half? Chance to make the 2nd fun

Yahooa day ago
BOSTON — The most important thing the Rays have accomplished to this point of the season is convincing their bosses they have a chance to reach the postseason.
Baseball operations president Erik Neander said as much while discussing Thursday's preemptive strike to bolster their beleaguered bullpen by acquiring Bryan Baker from Baltimore.
Advertisement
'It's a competitive group, and they have a chance to play postseason baseball and have a chance that if things break your way to do some damage in the postseason,' Neander said.
'You never want to take those opportunities for granted. We felt like this was an area where we could afford to help this team and felt like there was an opportunity to do it in a way that was aggressively responsible, and wanted to pull the trigger.'
That the Rays lost Thursday to Boston with Baker giving up the lead was rough initial feedback on the trade for the No. 37 pick in Sunday's draft. And it didn't help that there was another bullpen-caused loss Friday, when closer Pete Fairbanks served up a walkoff homer to Ceddanne Rafaela, extending their skid to 10 losses in 14 games.
Unlike most teams that — by words or actions — declare themselves as buyers or sellers leading up to the July 31 trade deadline, the Rays tend to take a more wide-open approach, often doing a bit of both.
Advertisement
What they've never really done — depending on how you view the 2021 acquisition of Nelson Cruz that kind of flopped, anyway — is take an all-in approach, where they fling open the door to the farm system by trading top prospects and/or take on hefty salary by adding veterans.
Could that change with this potentially being the final chance for principal owner Stuart Sternberg to hoist a trophy, should sales talks with Jacksonville developer Patrick Zalupski's group be consummated?
Do it for Stu?
Neander wouldn't say whether their plan has even been determined. For now, all he'll acknowledge is that they 'really like this team' and how the players have come together, and are willing to consider additional moves based on results leading up to the July 31 deadline.
Advertisement
'How the next few weeks go, obviously, are important,' Neander said. 'We often talk about the closer we are in the division (race), the more aggressive that we're typically willing to be.
'But we'll stay at it. We've got a few weeks to figure out how to make ourselves better, and we'll explore those avenues. Whether or that leads to action or not, time will tell.'
As if required by law, he added that the Rays also could consider deals that are more future-based, and assorted other combinations.
'Just can't help but always acknowledge that we're not always declarative or binary in the way we approach anything,' he said.
Advertisement
Pre-break recap
Though Sunday is Game 97 of 162, many baseball people still refer to the season in halves split by the All-Star break. That said, here's our recap of what's happened so far.
Most Valuable Ray
Second baseman Brandon Lowe and third baseman Junior Caminero did some good things. But there's no question the Rays' other All-Star position player, first baseman Jonathan Aranda, did the most. His consistent offense, high-quality at-bats, a handful of clutch hits and improved defense make him our easy choice.
Biggest disappointment (injury division)
The Rays had big plans for centerfielder Johnny DeLuca, who played all of nine games before being sidelined by a shoulder injury. But they had major expectations for starter Shane McClanahan. The two-time All-Star appeared to be back to ace form in spring training after missing 2024 recovering from Tommy John surgery. But he was forced off the mound in his final exhibition start due to a triceps nerve issue and is targeting an early August return.
Advertisement
Biggest disappointment (non-injury division)
Starter Taj Bradley and outfielder Christopher Morel's names come up, but reliever Edwin Uceta seems the clear winner based on the multiple games he helped lose. Last year, Uceta looked like a great find from the clearance rack. This year, with an ERA nearly four times higher (1.51 to 5.77 through Friday), his walks doubled (8 to 16) and homers soaring (2 to 9), not so much.
Most pleasant surprise
Caminero and Aranda have been better than expected. Drew Rasmussen, who wasn't assured a spot in the rotation, pitched his way to the All-Star Game. But the answer here lies with the trio of rookie outfielders — Jake Mangum, Kameron Misner and Chandler Simpson — who at various times sparked and even saved the team through a combination of their hitting, baserunning and fielding.
Advertisement
Season highlight
The answer for the romanticists is Misner's walkoff homer on opening day, making Steinbrenner Field actually feel like home. The answer for the realists was the June 18 game vs. Baltimore, when they fell behind 8-0 in the second inning and came back to win 12-8.
Rays rumblings
Condolences to the families on the recent passings of Lee Elia, the Devil Rays colorful hitting coach from 2003-05 under Lou Piniella; and Joe Coleman, the Triple-A Durham pitching coach and spring instructor from 2001-07. ... The Rays again are offering discounted tickets on Groupon. ... Zack Littell is 20th on mlbtraderumors.com's list of top trade candidates, Fairbanks 36th. Morel and Taylor Walls were honorable mentions. ... Related, McClanahan's return could line up with the Rays trading a starter at the deadline and/or facing the Dodgers Aug. 1-3. ... ESPN.com's David Schoenfield gave the Rays a B-plus in his midseason grades. ... After opening post-break play at home vs. the Orioles and White Sox, the Rays will play 19 of their next 22 games, and 25 of 33, on the road. ... Triple-A shortstop Carson Williams was fourth on The Athletic's list of top prospects who could be traded. ... Jeff Passan's ESPN.com list of trades to best fill needs has the Rays getting reliever Griffin Jax from the Twins and sending Taj Bradley to the Cardinals.
Advertisement
• • •
Sign up for our Sports Today newsletter to get daily updates on the Bucs, Rays, Lightning and college football across Florida.
Every weekday, tune into our Sports Day Tampa Bay podcast to hear reporter Rick Stroud break down the biggest stories in Tampa Bay sports.
Never miss out on the latest with your favorite Tampa Bay sports teams. Follow our coverage on X and Facebook.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biohaven Ltd. (BHVN) Collaborates with Bexorg, Inc to Target Central Nervous System Disorders
Biohaven Ltd. (BHVN) Collaborates with Bexorg, Inc to Target Central Nervous System Disorders

Yahoo

time19 minutes ago

  • Yahoo

Biohaven Ltd. (BHVN) Collaborates with Bexorg, Inc to Target Central Nervous System Disorders

Biohaven Ltd. (NYSE:BHVN) is one of the Best 52-Week Low Stocks to Buy According to Analysts.. On June 10, Biohaven Ltd. (NYSE:BHVN) announced that it has started a research collaboration with Bexorg, Inc. targeting central nervous system disorders. Bexorg, which is a techbio company, has a platform that can revive and study whole human and pig brains using artificial blood. This technology helps them see how drugs affect actual brain tissue. The platform produces deep data about how genes and proteins behave in disease and health. A pharmacist in a white coat with a range of drugs on shelves behind her. Both companies will use this technology to help design and test new therapies for CNS conditions. As a result of this collaboration, two Biohaven Ltd. (NYSE:BHVN) preclinical programs will benefit from these unique brain studies. Bexorg's approach offers a big leap ahead of normal lab models. Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company that develops and commercializes treatments for diseases in immunology, neuroscience, and oncology. While we acknowledge the potential of BHVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Sparrow expands coverage to five U.S. states, making it easier than ever for Americans to claim missing money
Sparrow expands coverage to five U.S. states, making it easier than ever for Americans to claim missing money

Yahoo

time19 minutes ago

  • Yahoo

Sparrow expands coverage to five U.S. states, making it easier than ever for Americans to claim missing money

Now available in Pennsylvania, Sparrow expands its secure, automated missing money platform to five states — with more on the way NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Sparrow, the secure platform that helps Americans claim missing money in minutes, has officially expanded to five states — with Pennsylvania the newest addition. The company's fully automated service now supports residents in California, Texas, Wisconsin, Nebraska, and Pennsylvania, with additional support for Georgia and Florida coming soon. With over $80 billion in unclaimed funds sitting idle — and 1 in 7 Americans estimated to have missing money — Sparrow offers a fast, safe, and frustration-free way to recover what's rightfully yours. Using cutting-edge technology and real-time financial data, Sparrow verifies your identity, retrieves the necessary documents on your behalf, and prepares your claim with minimal effort required. What used to take days — and often involved printing, mailing, or even visiting a notary — now takes most users under five minutes. 'We built Sparrow because the process of claiming lost money felt unnecessarily hard for everyday people,' said Will Nemirovsky, CEO. 'I ran into it myself in 2024, trying to claim a small refund — and it took hours of paperwork and frustration. We knew we could make it effortless and secure using modern technology and automation. Expanding to Pennsylvania is especially meaningful for me —it's where I met my Co-Founder, Jack Goettle.' Sparrow is fully licensed, offers risk-free pricing, and is committed to bank-grade encryption and secure data handling. Claims are processed through streamlined workflows that minimize human error and eliminate guesswork. Behind the scenes is a team of fintech veterans working to modernize a system that has failed everyday consumers for decades. To date, Sparrow has already helped users reclaim millions of dollars — and they're just getting started. Sparrow offers a success-based model: if your claim isn't paid, you don't pay. Check if you're owed money — it only takes a few minutes. Visit to get started. media@ Photos accompanying this announcement are available at: in to access your portfolio

Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)
Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)

Yahoo

time19 minutes ago

  • Yahoo

Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 14, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), while lowering the price target from $80 to $79. The firm held its positive outlook even after the recent challenge from the FDA's complete response letter for UX111 in Sanfilippo syndrome. The CRL was focused on specific chemistry, manufacturing, and controls issues. Importantly, the clinical data for UX111 was not questioned; however, the approval is still achievable once the CMC issues are resolved. A research team in a laboratory peering through microscopes at a biologic product. The analyst noted that the company is responding quickly and plans to address the CMC concerns and resubmit its Biologics License Application in the coming months. The analyst is also optimistic due to Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) robust pipeline. The company has promising programs for conditions like osteogenesis imperfecta and Angelman syndrome. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops treatments for rare and ultra-rare genetic diseases. They focus on biologics, small molecules, gene therapy, and nucleic acid products. While we acknowledge the potential of RARE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store